References
- Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008–11.
- Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 2006;72:1090–101.
- Takaesu G, Ninomiya-Tsuji J, Kishida S, et al. Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol 2001;21:2475–84.
- Jurida L, Soelch J, Bartkuhn M, et al. The activation of IL-1-induced enhancers depends on TAK1 kinase activity and NF-κB p65. Cell Rep 2015;10:726–39.
- Gupta S. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol 2002;22:185–94.
- Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question. Cell Mol Life Sci 2010;67:1567–79.
- Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005;7:1–18.
- Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012;33:522–30.
- Josephs SF, Ichim TE, Prince SM, et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med 2018;16:242.
- Wajant H. The role of TNF in cancer. Results Probl Cell Differ 2009;49:1–15.
- Totzke J, Gurbani D, Raphemot R, et al. Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-α inhibition for cancer and autoimmune disease. Cell Chem Biol 2017;24:1029–39.
- Melisi D, Xia Q, Paradiso G, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 2011;103:1190–204.
- Takahashi H, Jin C, Rajabi H, et al. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene 2015;34:5187–97.
- Iriondo O, Liu Y, Lee G, et al. TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 2018;9:1994.
- Ninomiya-Tsuji J, Kajino T, Ono K, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 2003;278:18485–90.
- Kamiyama H, Usui T, Sakurai H, et al. Epoxyquinol B, a naturally occurring pentaketide dimer, inhibits NF-kappaB signaling by crosslinking TAK1. Biosci Biotechnol Biochem 2008;72:1894–900.
- Buglio D, Palakurthi S, Byth K, et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 2012;120:347–55.
- Kilty I, Green MP, Bell AS, et al. TAK1 inhibition in the DFG-out conformation. Chem Biol Drug Des 2013;82:500–5.
- Tan L, Nomanbhoy T, Gurbani D, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem 2015;58:183–96.
- Schirmer A, Kennedy J, Murli S, et al. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA 2006;103:4234–9.
- Wissner A, Overbeek E, Reich MF, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003;46:49–63.
- Serafimova IM, Pufall MA, Krishnan S, et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol 2012;8:471–6.
- Bandyopadhyay A, Gao J. Targeting biomolecules with reversible covalent chemistry. Curr Opin Chem Biol 2016;34:110–6.
- Ha TH, Kim HS, Lee KI, et al. Novel imidazopyridine derivatives as a tyrosine kinase inhibitor, Patent WO2013100631A1, South Korea; 2013.
- Hornberger KR, Berger DM, Crew AP, et al. Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1. Bioorg Med Chem Lett 2013;23:4517–22.
- Bianco G, Forli S, Goodsell DS, Olson AJ. Covalent docking using autodock: two-point attractor and flexible side chain methods. Protein Sci 2016;25:295–301.